Beam Therapeutics ( (BEAM) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Beam Therapeutics shares are surging today after H.C. Wainwright reaffirmed its Buy rating and kept a bullish $80 price target on the stock, implying well over a doubling from where it trades now. Investors are also cheering tangible clinical progress, including the first patient dosed in a pivotal BEAM-302 trial and expected late-breaking data early September, all against a supportive rally in gene-editing names.
Looking ahead, Beam’s proprietary base-editing platform and growing clinical pipeline give the company multiple shots on goal and the chance to expand into several genetic disease markets, which could underpin its long-term growth story. However, heavy cash burn, ongoing losses, and reliance on partner-driven revenues mean Beam will likely need more funding and successful collaborations before its promising science can fully translate into stable, self-sustaining performance for shareholders.
More about Beam Therapeutics
YTD Price Performance: 2.20%
Average Trading Volume: 2,165,201
Technical Sentiment Signal: Buy
Current Market Cap: $3.07B
For further insights into BEAM stock on
TipRanks’ Stock Analysis page.
See more of today’s
top stock gainers and losers.